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coronary artery spasm (Table 1). However, when adjusted by age, the
statistical signiﬁcance disappeared (OR, 0.965; 95% CI, 0.898-1.037 ;
P-value, 0.335). The incidence of MACE was 11.1% in male gender
and 8.6% in female gender. In male gender, the serum uric acid
level between the groups with and without MACE was similar but in
female gender, the level of uric acid was higher in the group with
MACE, compare to the group without MACE. However, when
adjusted by age, uric acid was not associated with MACE (Table 2).
CONCLUSIONS In our study, uric acid was neither the risk factor nor
prognostic factor for clinical outcomes during 3-year follow-up period
in coronary vasospastic angina regardless of gender.
CATEGORIES CORONARY: Acute Coronary Syndromes
KEYWORDS Risk factors, Vasospastic angina
TCT-182
One-year Outcomes With Prasugrel (Pre-)Treatment in Routine Practice:
Early Results from the Dutch, Multicenter and Observational Rijnmond
Collective Cardiology Research (CCR) Study
Tuncay Yetgin,1 Arie G. de Vries,2 Pieter C. Smits,3 Eric Boersma,4
Robert J. Van Geuns,5 Felix Zijlstra,6 Marc van der Linden6
1Thoraxcenter, Erasmus Medical Center, Rotterdam, Zuid-Holland;
2Albert Schweitzer Hospital, Dordrecht, Z-H; 3Maasstad Hospital
Rotterdam, Rotterdam, Netherlands; 4Thoraxcenter Cardiology,
Rotterdam, Netherlands; 5Erasmus MC, Rotterdam, Netherlands;
6Erasmus University Medical Center, Rotterdam, Netherlands
BACKGROUND Increased platelet inhibition by prasugrel has been
shown to result in reduced ischemic events along with greater
bleeding hazards in patients with acute coronary syndromes (ACS)
treated with percutaneous coronary intervention (PCI). Yet, there is
limited experience with the use of prasugrel in routine practice. We
evaluated 1-year outcomes with routine prasugrel treatment after ACS
in a large-scale registry.
METHODS The Rijnmond Collective Cardiology Research (CCR) regis-
try is a prospective, observational study with enrollment of 4,259 PCI-
treated ACS patients with 1-year follow-up in the larger region of Rot-
terdam, the Netherlands. Based on implemented hospital protocols, all
patients received prasugrel as ﬁrst-choice antiplatelet agent, unless
contraindicated, including pretreatment before arrival at cathlab either
pre-hospital (ambulance), in referring hospital or in-hospital (emer-
gency room or coronary care unit), whenever possible. All events are
validated by an independent clinical endpoint committee.
RESULTS A total number of 2729 patients (64%) received prasugrel in
the registry after the index event. Half of these patients presented with
ST-elevation myocardial infarction, 77% were men, and mean age was
60.110.8 years. Reasons for not subscribing prasugrel included, for
instance, age >75 years (n¼611 [42% of pts receiving clopidogrel]) and
previous stroke or TIA (n¼270 [18.4%]). At the time of current abstract
submission, 70% of all study events were validated. At 1 year, the pri-
mary endpoint, a composite of all-cause death and myocardial infarc-
tion, occurred in 2.9% of patients receiving prasugrel. All-cause deathoccurred in 2.0%, myocardial infarction in 1.0%, target-vessel revas-
cularization in 2.1%, stent thrombosis in 0.5%, and stroke in 0.3% of the
prasugrel-treated patients. The safety endpoint of all Thrombolysis in
Myocardial Infarction major bleeding episodes, whether related or not
related to coronary-artery bypass grafting was observed in 1.1% of pa-
tients receiving prasugrel. At TCT 2015, the remaining events will be
validated and available for presentation.
CONCLUSIONS Early results from the CCR study show that prasugrel-
treated ACS patients have low rates of ischemic events, including
overall mortality, and no excess rates of major bleeding in routine
practice up to 1 year post-PCI.
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BACKGROUND Coronary artery disease (CAD) is a serious public and
economic health problem. Coronary angiography is a gold standard for
diagnosing CAD and is indicated in patients with 61-90% pre-test
probability of the disease when the diagnosis cannot be made on
clinical grounds alone and when revascularization is being consid-
ered. Around 25% of coronary angiograms demonstrate normal ar-
teries. The natural history of normal coronary angiogram is poorly
understood. We evaluated the progression of disease in patients with
normal coronary angiography and assessed the overall survival and
event-free survival from acute myocardial infarction in these patients.
METHODS We interrogated the Central Cardiac Audit Database
(CCAD) between November 2005 and December 2013 to identify pa-
tients with normal or ’near-normal’ coronary angiography. De-
mographic, clinical and angiographic data was recorded. This
database was linked with the Patient Episode Database for Wales
(PEDW) and the datasets from the Ofﬁce for National Statistics (for
mortality) using the Secure Anonymized Information Linkage (SAIL)
databank. This allowed for the extraction of information from all the
sources above on the basis of the International Statistical Classiﬁca-
tion of Diseases (ICD-10) using the Structured Query Language (SQL).
RESULTS Out of over 20,000 patients undergoing coronary angiog-
raphy between November 2005 and December 2013, 5032 patients had
normal coronaries and minor CAD. Of 5032 patients, 136 underwent
repeat angiography, with 131(96.3%) and 5(3.7%) patients having two
and three repeat investigations respectively. Mean time between
procedures was 3.3 (1.82) years. Of those 136 patients, at the median
follow up of 6.8 years, no change in disease progression was
demonstrated in 108(79.4%) patients on the follow up studies. In the
remaining 28 (20.6%) patients, normal coronaries progressed to minor
CAD. No patients progressed beyond minor CAD. Patients with normal
coronaries had signiﬁcant better survival than patients with minor
CAD (p<0.05), but survival free from MI was >99.5% in both groups at
the median of 5 years follow up. (p¼0.09)
CONCLUSIONS Normal coronary angiography and minor CAD is un-
likely to progress to signiﬁcant disease at 7 years and the incidence of
MI in these patients is rare at 5 years. Therefore, repeating coronary
angiography within at least 5 years is not indicated.
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(DAPT) after drug eluting stent (DES) implantation in patients with or
without acute coronary syndromes (ACS) is unknown. We aim to
evaluate the efﬁcacy and safety of long duration DAPT (L-DAPT)
compared to short duration DAPT (S-DAPT) after drug-eluting stent
(DES) implantation in patients who presented with or without ACS.
METHODS We searched Medline, Embase, and Cochrane Central
Register of Controlled Trials (CENTRAL) to identify randomized
controlled trials (RCTs) assessing the effect of L-DAPT versus S-DAPT
after DES in patients who presented with ACS and non-ACS. Primary
efﬁcacy endpoints were stent thrombosis (ST), myocardial infarction
(MI), target vessel revascularization (TVR), all-cause mortality and
cardiac mortality. Primary safety endpoints were major bleeding and
stroke. Event rates were compared using a random effects model.
RESULTS We identiﬁed 3 RCTs (DAPT, ITALIC, RESET) in which
15,587 patients were randomized to S-DAPT versus L-DAPT (4,969 ACS
and 10,618 non-ACS). Clinical outcomes with S-DAPT compared with
L-DAPT in ACS and non-ACS are summarized in table.
Table. Clinical outcomes with S-DAPT compared with L-DAPT in patients with ACS and non-ACSAll patients
(n[15,587)ACS
(n[4,969)Non-ACS
(n[10,618) Pinteraction Hetero-geneity (I2)All-cause mortality 13,470 1.36 [0.59, 3.14] 0.70 [0.50, 0.97] 0.15 52.7%Cardiac mortality 15,587 1.69 [0.82, 3.50] 0.89 [0.57, 1.37] 0.14 55.2%MI 15,587 2.29 [1.58, 3.34] 1.64 [1.25, 2.15] 0.16 50.1%Stent thrombosis 15,587 3.70 [1.83, 7.48] 1.79 [0.45, 7.02] 0.35 0%TVR 3939 5.04 [1.28, 19.76] 0.89 [0.51, 1.55] 0.02 81.2%Stroke 1822 0.33 [0.01, 8.23] 0.14 [0.01, 2.74] 0.70 0%TIMI major
bleeding1822 0.33 [0.01, 8.23] 0.20 [0.01, 4.13] 0.82 0%Gusto major
bleeding11,648 0.70 [0.30, 1.65] 0.65 [0.37, 1.14] 0.88 0%MI ¼ myocardial infarction; TVR ¼ target vessel revascularization
CONCLUSIONS In the present analysis of RCTs in which patients were
analyzed according to clinical syndrome acuity, S-DAPT was associ-
ated with higher rates of ST and MI, lower rates of major bleeding, and
non-signiﬁcant differences in mortality, with no signiﬁcant in-
teractions according to ACS vs non-ACS. However, in non-ACS pa-
tients the beneﬁt-risk proﬁle favored S-DAPT, with lower all-cause
mortality, where the trends were reversed in ACS. Additional studies
are required to determine if the beneﬁt-risk proﬁle of S-DAPT vs. L-
DAPT varies according to clinical syndrome.
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BACKGROUND Use of new generation of DES is related with favorable
outcomes in patients with ST-elevation myocardial infarction
(STEMI). We sought to assess 1-year clinical outcomes in this patient
subset, treated with bioresorbable polymer Nobori DES in a large
worldwide registry.
METHODS Among a total of 12122 patients treated with Nobori DES in
the large, prospective, single-arm, multi-center eNOBORI registry,
1292 (10.7%) had STEMI. All endpoint related adverse events were
adjudicated by an independent clinical events committee. The pri-
mary endpoint was target lesion failure (TLF) at 1 year.
RESULTS STEMI patients were younger (60.6 vs 63.7 years; p<0.01),
with higher percentage of males (79.1% vs 76.1%; p¼0.016), and more
current smokers (45.3% vs 24.4%; p<0.01) than non-STEMI patients.
STEMI patients had less diabetes (22.1% vs 33.9%), hypertension
(51.3% vs 73.8%), hypercholesterolemia (46.5% vs 64.8%), renal fail-
ure (4.8% vs 7.7%) and peripheral vascular disease (4.7% vs 8.8%)
comparing with non-STEMI patients (p<0.01 for all). STEMI patients
had also fewer previous history of MI (10.1% vs 30.6%) and coronary
revascularization (9.1% vs 32.3%) (p<0.01 in both). The pain-to-
balloon time was <3 hours in 37%, between 3 and 6 hours in 22%,
between 6 and 12 hours in 13% and >12 hours in 19% of STEMI pa-
tients. The median door-to-balloon time was 50 minutes. Lesions
were complex (60.2% type B2/C), with 25.3% moderate or severe
calciﬁed lesions, and 50.0% contain-ing thrombus. Low perfusion(TIMI 0/1) was observed in 47.2% of lesions before procedure, while
after procedure TIMI 3 ﬂow was achieved in 95.3%. 49.1% STEMIs
were located in anterior and 39.6% in inferior walls. 43.4% of all
STEMI patients received adjunctive treatment including: hemody-
namic support (8.9%), intravenous thrombolysis (14.6%), pre-proce-
dural GP IIB/IIIa inhibitor (9.9%) and/or others (15.5%). Thrombus
aspiration was performed in 26.8% of lesions. At 1 year follow up, in
STEMI patients the rate of cardiac death was 2.0%, target vessel MI
was 1.2%, target lesion revascularization (TLR) was 1.4% and target
vessel revascularizations (TVR) was 2.0%. The observed 1 year target
lesion failure (TLF) rate was 4.0%. Deﬁnite or probable stent throm-
bosis rate was low (0.85%). In non-STEMI patients those rates were:
cardiac death 1.0%, target vessel MI 1.1%, TLR 1.4% and TVR 2.1%
respectively. TLF rate was 3.3% and deﬁnite or probable stent
thrombosis was 0.43%.
CONCLUSIONS Despite a high risk patient subgroup, STEMI patients
treated with Nobori DES had favorable clinical outcomes and low rate
of stent thrombosis at 1 year. These data provided safety and efﬁcacy
evidence for the use of bioresorbable polymer DES in this complex
patient subset.
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BACKGROUND It has been proven that presence of chronic total oc-
clusion (CTO) in other than infarct-related artery (IRA) in patients
with NSTEMI is associated with higher rates of in-hospital and long-
term mortality than in patients without CTO. However, there is a lack
of data regarding the inﬂuence of the number of untreated CTOs on
early and long-term prognosis in NSTEMI population. Therefore the
aim of the study was to comprehensively evaluate the effect of the
number of CTOs on 12-month major adverse cardiac events (MACE) in
patients with non-ST-segment elevation myocardial infarction
(NSTEMI) and multivessel coronary artery disease (MV CAD) treated
with percutaneous coronary intervention (PCI).
METHODS The consecutive data of 1242 patients with NSTEMI
admitted to the Clinic between 2006 and 2012 were analyzed. Only
patients with CTO and MV CAD treated with PCI were included for
further analysis. The differentiation between CTO and acute occlusion
was determined by the compilation of the occlusion morphology,
electrocardiographic recording and a possible history of previously
documented acute coronary events in the same artery. Patients with a
history or qualiﬁed to coronary artery bypass grafting during hospital-
ization were excluded from further analysis. 545 patients met all study
criteria and were divided according to the number of CTOs in coronary
angiography: CTO¼0 (n¼314) –without CTO, CTO¼1 (n¼179) –with only
one documented CTO and CTO2 (n¼52)- with more than one CTO.
RESULTS Baseline clinical and angiographic characteristic differenti-
ated signiﬁcantly between studied groups. Patients withmore than one
CTO had signiﬁcantly higher risk according to GRACE score (CTO¼0:
114.2  31.0 pts., CTO¼1: 121.6  33.4 pts., CTO2: 124.7  25.5 pts.,
p¼0.0085). Furthermore, similar trend in the CRUSADE bleeding score
was observed (CTO¼0: 25 [17 – 36] pts., CTO¼1: 28 [18 – 40] pts., CTO2:
32 [21 – 39] pts., p¼0.028). The incidence of 12-monthMACEwas highest
in CTO2 group (CTO¼0: 22.6%, CTO¼1: 27.4%, CTO2: 40.4%,
p¼0.0088), which was mainly driven by higher mortality rate (CTO¼0:
8.3%, CTO¼1: 13.4%, CTO2: 26.9%, p¼0.0002). There were no signif-
icant differences in percentage of 12-month myocardial infarction
(p¼0.96) and revascularization caused by acute coronary syndromes
(p¼0.81) in analyzed groups. After multivariate adjustment for differ-
ences in the baseline characteristics, the number of CTOs was an in-
dependent factor of 12-month mortality (per 1 CTO more; hazard ratio
[HR]: 1.45, 95% conﬁdence interval [CI]: 1.01 – 2.10; p¼0.045).
CONCLUSIONS In patients with NSTEMI and MV CAD treated with
PCI greater number of CTO localized in non-IRA was associated with
higher incidence of 12-month MACE and was an independent factor
affecting 12 month mortality.
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